Over the last 7 days, the United States market has dropped 4.1%, though it has risen by 21% over the past year with earnings forecast to grow by 18% annually. For investors willing to look beyond established companies, penny stocks can present intriguing opportunities, despite their somewhat outdated label. These stocks often represent smaller or newer companies that may offer surprising value and potential for growth when backed by solid financial foundations.

Let's explore several standout options from the results in the screener.

Taboola.com (TBLA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taboola.com Ltd. operates an artificial intelligence-based algorithmic engine platform across various countries, including Israel, the United States, the United Kingdom, and Germany, with a market cap of approximately $1.28 billion.

Operations: The company's revenue is derived from its advertising segment, which generated approximately $1.95 billion.

Market Cap: $1.28B

Taboola.com Ltd., with a market cap of US$1.28 billion, has demonstrated robust financial performance, reporting US$466.4 million in Q1 2026 sales and a net income of US$59.07 million, reversing a loss from the previous year. The company operates with significant cash flow coverage for its debt and has not experienced shareholder dilution recently. Its earnings growth in the past year was substantial due to one-off gains, although future earnings are expected to decline slightly over three years. Taboola's AI-driven platform innovations like Realize+ aim to enhance advertiser engagement and revenue potential across global markets.

UP Fintech Holding (TIGR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: UP Fintech Holding Limited offers online brokerage services primarily for Chinese investors across New Zealand, the Cayman Islands, Singapore, the United States, and other international markets, with a market cap of approximately $840.19 million.

Operations: The company generates revenue of $567.88 million from its brokerage services.

Market Cap: $840.19M

UP Fintech Holding Limited, with a market cap of US$840.19 million, recently reported Q1 2026 revenue of US$154.88 million but faced a net loss of US$26.85 million compared to the previous year's profit. Despite this setback, the firm has shown strong historical earnings growth and maintains substantial cash reserves exceeding its total debt, supporting financial stability. The company announced a US$50 million share repurchase program funded by available cash, indicating confidence in its valuation and potential for shareholder value enhancement amidst stable weekly volatility and experienced board oversight.

Treace Medical Concepts (TMCI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Treace Medical Concepts, Inc. is a medical technology company that designs, manufactures, and markets medical devices in the United States with a market cap of $241.98 million.

Operations: The company's revenue of $207.32 million is generated from its operations in designing, manufacturing, and marketing medical devices.

Market Cap: $241.98M

Treace Medical Concepts, Inc., with a market cap of US$241.98 million, remains unprofitable with increasing losses over the past five years. Recent Q1 2026 earnings showed a decline in sales to US$47.2 million and a net loss of US$17.96 million compared to the previous year. Despite financial challenges, Treace has sufficient cash runway for over two years and stable short-term asset coverage exceeding liabilities. The company is advancing its product line with the SuperBite Compression Screw System and SpeedXM Midfoot Fusion System launches expected later in 2026, potentially expanding its addressable market by an estimated US$300 million.

Key Takeaways

• Access the full spectrum of 334 US Penny Stocks by clicking on this link.
• Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.